Article Sidebar

pdf
Date Published: 02/12/2025
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v556i1.16275
Issue
Vol. 556 No. 1 (2025)
Section
Các bài báo
How to Cite
Phạm, T. T. H. (2025). FACTORS ASSOCIATED WITH SECUKINUMAB TREATMENT RESPONSE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AT NGHE AN GENERAL FRIENDSHIP HOSPITAL. Vietnam Medical Journal, 556(1). https://doi.org/10.51298/vmj.v556i1.16275

FACTORS ASSOCIATED WITH SECUKINUMAB TREATMENT RESPONSE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AT NGHE AN GENERAL FRIENDSHIP HOSPITAL

Thị Thanh Huyền Phạm

Main Article Content

Abstract

FRIENDSHIP HOSPITAL


Objective: This study aimed to investigate factors associated with treatment response in patients with moderate-to-severe plaque psoriasis treated with secukinumab at Nghe An General Friendship Hospital. Subject and Methods: A cross-sectional analytical study was conducted on 60 patients aged ≥18 years, clinically diagnosed with moderate-to-severe plaque psoriasis and treated with secukinumab. Factors assessed included age, sex, disease duration, body mass index (BMI), smoking, and alcohol consumption. Treatment efficacy was evaluated by the proportion of patients achieving PASI 75 at week 16. Statistical analyses included Chi-square/Fisher’s exact test and multivariate logistic regression. Results: The mean age of patients was 52.0 ± 14.1 years; 73.3% were male. The mean BMI was 23.3 ± 2.1 kg/m², with 15.0% overweight/obese. Smoking and alcohol consumption were reported in 25.0% and 28.3% of patients, respectively. Patients with normal BMI achieved a significantly higher PASI 75 response compared with overweight/obese patients (90.0% vs. 65.0%; p<0.05). Non-smokers and non-drinkers had higher PASI 75 rates compared with smokers (85.0% vs. 60.0%) and drinkers (88.0% vs. 62.5%) (p<0.05). Multivariate logistic regression identified BMI ≥25 as an independent factor associated with reduced likelihood of achieving PASI 75 (OR=0.08; 95% CI: 0.01–0.45; p=0.004). Other factors (age, sex, smoking, alcohol consumption) showed a trend of influence but did not reach statistical significance. Conclusion: The efficacy of secukinumab in plaque psoriasis is influenced by multiple factors, with BMI ≥25 being an independent prognostic factor reducing treatment response. These findings highlight the importance of weight management, along with counseling for smoking cessation and alcohol reduction, to optimize therapeutic outcomes in patients with moderate-to-severe plaque psoriasis

Article Details

Keywords

Plaque psoriasis, Secukinumab, PASI 75, Body mass index, Associated factors.

References

Hägg, D., Sundström, A., Eriksson, M., & Schmitt-Egenolf, M. (2017). Severity of psoriasis differs between men and women: A study of the Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. American Journal of Clinical Dermatology, 18(4), 583–590.
2. Owczarczyk-Saczonek, A., & Placek, W. (2017). Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw, 71(1), 761–772.
3. Körber, A., & Andreas, M. A. (2021). Treatment of psoriasis with secukinumab: Practical guidance. Hautarzt, 72(11), 984–991.
4. Al‐Mutairi, N., & Nour, T. (2014). The impact of weight loss on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled trial. Expert Opinion on Biological Therapy, 14, 749–756.
5. Zhou, H., Wu, R., Kong, Y., Zhao, M., & Su, Y. (2020). Impact of smoking on psoriasis risk and treatment efficacy: A meta-analysis. Journal of International Medical Research, 48.
6. Michalski, P., & Palazzo-Michalska, V. (2023). Impact of alcohol consumption, smoking, and diet on the severity of plaque psoriasis: A comprehensive assessment using clinical scales and quality of life measures. Medical Science Monitor, 29.